Minerva Neurosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States under the ticker NERV. For French-speaking investors in France, Belgium, and Switzerland, it should be viewed as a high-risk, catalyst-driven small-cap biotech whose valuation is primarily tied to clinical execution, regulatory progress, and financing capacity. The company was incorporated in Delaware and is headquartered in Burlington, Massachusetts. Its business is centered on identifying, developing, and ultimately commercializing product candidates for central nervous system disorders, with an emphasis on areas of significant unmet medical need. The company’s core asset is roluperidone, its lead program for the treatment of negative symptoms in schizophrenia. Minerva is attempting to develop a differentiated therapy in a segment that has historically been underserved, which could create meaningful upside if clinical and regulatory milestones are achieved. The company also holds exclusive rights to MIN-301 for Parkinson’s disease, and it previously co-developed seltorexant with Janssen Pharmaceutica NV for insomnia disorder and adjunctive treatment of major depressive disorder. In practical terms, however, Minerva remains a largely single-asset story, meaning the investment case is highly concentrated around roluperidone. From a historical standpoint, Minerva is part of the U.S. biotech model built around focused neuroscience programs and value creation through regulatory approvals rather than current commercial revenues. The company states that it has not yet obtained marketing approval for any of its product candidates and has not generated revenue from product sales. As a result, its financial profile remains dependent on external capital and on the successful advancement of its pipeline. That makes the stock particularly sensitive to trial outcomes, FDA feedback, and cash runway. Recent developments underscore this profile. In February 2024, the FDA issued a Complete Response Letter for the roluperidone NDA, which pushed Minerva to continue discussions with the agency and work toward an additional confirmatory Phase 3 study. Company updates in 2025 and 2026 indicate that management is still advancing the program, preparing for the confirmatory trial, and working toward a possible NDA resubmission. The company also highlighted in its latest disclosures that funding the clinical program, the regulatory process, and general operations remains a key priority. For investors, NERV is therefore best understood as a development-stage NASDAQ biotech in the United States with a concentrated neuroscience pipeline, meaningful binary-event risk, and upside that depends on regulatory success rather than current commercial traction.